全球新药王。
MRK Q4 Earnings Full year Keytruda Sales Grew 19% to $25B; Excluding the Impact of Foreign Exchange, Sales Grew 21%。单品250亿美金的抗体，难以想象。K药PD-1$默沙东(MRK)$
| 发布于: | Android | 转发：1 | 回复：1 | 喜欢：0 |
全球新药王。
MRK Q4 Earnings Full year Keytruda Sales Grew 19% to $25B; Excluding the Impact of Foreign Exchange, Sales Grew 21%。单品250亿美金的抗体，难以想象。K药PD-1$默沙东(MRK)$
默沙东